Novavax (NVAX) Gross Margin (2011 - 2026)

Novavax's Gross Margin history runs 11 years deep, the most recent figure standing at 78.0% for Q1 2026.

• On a quarterly basis, Gross Margin fell 1988.0% year-over-year to 78.0% in Q1 2026; TTM through Mar 2026 was 83.16%, a 428.0% decrease from a year earlier, with the FY2025 full-year figure at 93.5%, up 2322.0% from the prior year.
• Gross Margin fell to 78.0% in Q1 2026 per NVAX's latest filing, from 84.98% in the prior quarter.
• Across five years, Gross Margin topped out at 97.88% in Q1 2025 and bottomed at 45.8% in Q2 2022.
• The 5-year median for Gross Margin is 58.48% (2024), against an average of 59.69%.
• Across the five-year window, Gross Margin sank 14580 bps in 2022 and jumped 13266 bps in 2023, its largest moves.
• Year by year, Gross Margin stood at 49.14% in 2022, then decreased by 5 bps to 46.81% in 2023, then climbed by 25 bps to 58.48% in 2024, then jumped by 45 bps to 84.98% in 2025, then declined by 8 bps to 78.0% in 2026.
• Per Business Quant, the three latest NVAX Gross Margin figures stand at 78.0% (Q1 2026), 84.98% (Q4 2025), and 69.49% (Q3 2025).